Filing Flows › Akebia Therapeutics (AKBA) › Who owns the stock
Who owns Akebia Therapeutics (AKBA) stock
162 funds reported Akebia Therapeutics (AKBA) shares in their latest 13F filings, worth $160M in all. The largest holder is Vanguard Group ($25.8M). Last quarter 96 funds added to their stakes and 58 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Vanguard Group | 16,016,448 | $25.8M | increase | 2025-12-31 |
| BlackRock | 19,986,374 | $22.8M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 11,322,143 | $12.9M | increase | 2026-06-30 |
| Alerce Investment Management, L.P. | 5,747,906 | $10.9M | unchanged | 2024-12-31 |
| AQR Capital Management LLC | 9,151,524 | $10.4M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 6,727,302 | $7.7M | increase | 2026-06-30 |
| State Street | 5,390,853 | $6.1M | decrease | 2026-06-30 |
| Jacobs Levy Equity Management | 4,273,026 | $4.9M | increase | 2026-06-30 |
| Nantahala Capital Management, LLC | 4,000,000 | $4.6M | increase | 2026-06-30 |
| Acadian Asset Management LLC | 4,004,867 | $4.6M | increase | 2026-06-30 |
| Goldman Sachs Group | 3,689,167 | $4.2M | increase | 2026-06-30 |
| Millennium Management LLC | 3,196,605 | $3.6M | increase | 2026-06-30 |
| Vanguard Portfolio Management LLC | 2,533,977 | $2.9M | increase | 2026-06-30 |
| Two Sigma Investments, LP | 2,436,673 | $2.8M | increase | 2026-06-30 |
| Charles Schwab Investment Management | 2,300,438 | $2.6M | increase | 2026-06-30 |
Akebia Therapeutics' latest quarter
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most AKBA stock?
By the latest 13F filings: Vanguard Group ($25.8M); BlackRock ($22.8M); Vanguard Capital Management LLC ($12.9M); Alerce Investment Management, L.P. ($10.9M); AQR Capital Management LLC ($10.4M).
What is the short interest in AKBA?
23,071,255 shares were sold short at the 2026-10-15 settlement, 2.62% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.